The
Novartis field has experienced a series of significant events recently. In their
Phase III C3 glomerulopathy (C3G) trial, the oral Fabhalta(R) drug has documented meaningful results for a year. Despite falling slightly, Novartis' stocks have indicated promising
long-term momentum. Additionally,
Mediolanum International Funds Ltd and
Eastern Bank have invested $24.10 million and a new undisclosed amount respectively in Novartis. Despite certain setbacks, the company's stock remains
strong with investors, and it's investor base appears to grow, with individual investors owning the majority of shares. The company expects favourable earning results for Q3 2024 and increased
profit forecasts for 2024, an aspect which led to a raised guidance. Novartis also announced the
acquisition of MorphoSys. On an unfortunate information, Novartis' stock ratings were downgraded by both Jefferies and BofA. However, the company continues to perform well with approval of drugs such as Kisqali for early breast cancer and Fabhalta, on top of positive Q2 earnings.
Novartis Stocks News Analytics from Tue, 09 Jan 2024 08:00:00 GMT to Sat, 26 Oct 2024 21:50:00 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -3
